NRIX Institutional Ownership
Nurix Therapeutics, Inc.
Latest close $24.69 as of Aug 4, 2026
Schedule 13G/13D reports beneficial ownership at an observation date. “Accumulation” or “reduction” is inferred
from changes in reported shares when available; it is not a list of individual trades or exact execution prices.
Form 13F rows are quarter-end holding context only and do not establish an exact entry date.
Free access includes current parsed ownership filings, reported share changes, and ownership-percentage changes.
Significance scoring, disclosure-speed analysis, confirmation/divergence signals, and signal alerts require Investor or Pro.
Compare plans.
Cross-institution intelligence
Institutional Research
Each institution is compared with its own prior filing, then the latest institution-level directions are compared for breadth.
Latest filing
Jul 31, 2026
Investor and Pro research
See whether tracked institutions agree.
Compare each institution with its own prior filing, measure accumulation breadth, and view ownership and activity charts across holders.
3 tracked institutions
Latest filing Jul 31, 2026
Beneficial ownership filing history
Showing 3 of 4 parsed filing(s) · 1 older require more history access| Holder | Observed / filed | Reported change | Shares | Ownership | Observation | Filing | Latest |
|---|---|---|---|---|---|---|---|
| Vanguard Capital Management CIK0002100119 | Jun 30, 2026 observed Jul 31, 2026 filed · 31d Initial Schedule 13G | Initial Schedule 13G | 5.2M | 12.00% | $24.26 | $23.21 | $24.69 |
| Fidelity / FMR CIK0000315066 | Mar 31, 2026 observed May 6, 2026 filed · 36d Initial Schedule 13G | Initial Schedule 13G | 5.5K | 12.00% | $15.50 | $16.88 | $24.69 |
| BlackRock Legacy CIK0001364742 | May 31, 2024 observed Jun 7, 2024 filed · 7d Schedule 13G amendment | Reported accumulation | 6.0M +1.4M | 10.20% +0.60 pts | $15.68 | $24.69 |